OncoGenome Sciences says it completed a $16 million funding and is changing its name to OncoMethylome Sciences.

The OncoMethylome Sciences laboratory and headquarters are in Liège, Belgium and its USA offices are in Durham. It is backed by ING Belgium, Polytechnos Venture Partners, Germany, Life Science Partners Management(a Dutch venture capital fund) and three Belgian Venture funds, Technowal, Meusinvest and S.I.B.L.

The company says it has appointed Harry Schrickx vice president of business development and marketing.

OncoMethylome says the its new name better explains the company’s focus on cancer detection using its own technology of hyper-methylation.

Its gene methylation tests detect cancer at a much earlier stage of the disease and at a higher level of accuracy than currently available tests, or that predict and monitor response to cancer therapy for optimal and more individualized treatment decisions.

Oncomethylome Sciences